chemieunternehmen.com

The 11th edition is dedicated to our exciting new capabilities in the biologics lane of Evotec’s “Multi-modality Autobahn.”  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-publishes-ddup-11—ai-driven-antibody-discovery-at-evotec-6098

Evotec partner Bayer today reported more detailed results from PAGANINI, the Phase IIb dose-finding study evaluating the efficacy and safety of eliapixant in patients with refractory chronic cough (“RCC”). Eliapixant (BAY1817080) is an investigational orally administered, potent and selective P2X3 receptor antagonist derived from a former multi-target research collaboration between Bayer and Evotec.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-partner-bayer-phase-iib-trial-shows-eliapixant-significantly-decreases-cough-frequency-in-patients-with-refractory-chronic-cough-6096

Evotec SE announced today that Bristol Myers Squibb Company has exercised its option to enter into an exclusive global license for EVT8683 which comes from a broader neurodegeneration collaboration. EVT8683 is a small molecule targeting a key cellular stress response that holds great promise in various neurodegenerative indications and is ready to enter clinical development. The programme originated from a phenotypic screening approach based on Evotec’s leading iPSC platform and reached IND filing within only 5 years. Under an option agreement with Celgene (which is now a Bristol Myers Squibb company), Bristol Myers Squibb has rights to additional programmes in neurodegenerative diseases. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-announces-bristol-myers-squibb-opt-in-of-evt8683-as-the-first-programme-from-ipsc-based-neurodegeneration-collaboration-6090

Evotec partner Kazia Therapeutics Limited today announced that the planned phase I study for EVT801 has received full approval from L’Agence Nationale de Sécurité du Médicament et des Produits de Santé (“ANSM”), the French regulatory agency. The study is expected to open to recruitment by the end of CY2021. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-partner-kazia-therapeutics-announces-full-regulatory-approval-for-phase-i-study-of-evt801-6092

Evotec SE and Secarna Pharmaceuticals GmbH & Co. KG („Secarna“), a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide („ASO“) therapies to address challenging or previously undruggable targets via its LNAplus™ platform, have expanded their strategic partnership in the field of ASO-based therapeutics. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-secarna-pharmaceuticals-expand-strategic-partnership-in-the-field-of-antisense-drug-discovery-6094